Investing.comQwen · 实盘不做把握 2/10不做原因:证据不足
北京时间·🕒 发布 19:36:41·⟳ 抓取 19:37:26 +45s·⚡ 决策 09-01 19:41:37 +4m11s·55.9 天前
Stoke Therapeutics与Biogen宣布将在欧洲癫痫大会展示zorevunersen治疗Dravet综合征的4年1/2a期数据
事件为1/2a期开放标签扩展研究的会议前预告性新闻稿，证据等级低（无对照组、选择偏倚），3期EMPEROR数据要到2027年Q3才读出；94%患者CSF蛋白升高是潜在安全信号；对Biogen完全不可见；STOK报价不可得；美股尚未开盘。不存在可交易的短期催化。
📄 原文Investing.com↗ 原文
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome
Fed hike bets, oil rally and Japan yields - what’s moving markets BEDFORD, Mass. and CAMBRIDGE, Mass. - Stoke Therapeut…
不做 Stoke Therapeutics（STOK.US）
1/2a期开放标签扩展数据证据等级极低（无对照组、选择偏倚），仅为会议前预告；3期EMPEROR数据要到2027年Q3；94%CSF蛋白升高为潜在安全隐忧；Futu无法取得实时报价，交易可行性存疑。不存在短期可交易催化。
不做 Biogen（BIIB.US）
Dravet综合征为超罕见病（约1/16000），即使zorevunersen获批，峰值销售对Biogen百亿美元级收入完全不可见（估计峰值<$5亿，占收入<2%）；且3期数据尚在1年后，当前无任何催化意义。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Stoke/Biogen发布会议前新闻稿，宣布将在9月5-9日欧洲癫痫大会展示zorevunersen的4年1/2a期开放标签扩展数据。数据显示患者留存率尚可（93%继续治疗），但开放标签扩展研究无对照组、存在选择偏倚，证据等级极低。94%患者出现CSF蛋白升高虽无严重临床表现，仍是潜在安全隐忧。关键3期EMPEROR研究结果预计2027年Q3，距今超过一年。对Biogen而言，超罕见病（1/16000发病率）早期数据对百亿美元级收入完全不可见。STOK在Futu无实时报价，美股当前处于盘前。综合判断：无短期可交易催化，无跨市场映射，AVOID。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 94%患者出现CSF蛋白升高，虽公司称无严重临床表现，但可能在3期数据读出时成为监管关注点
- 1/2a期开放标签扩展数据无对照组，疗效结论不可靠，3期结果可能与早期趋势不一致
先例如何影响了这次决策
对本次决策的影响:先例缺失不改变AVOID结论，因为事件本身证据等级过低、3期数据远在1年后，不构成短期催化
方向:无可用先例
涨幅量级:无法校准幅度
形态:无法判断
工具执行结果 · 成功 3 · 降级 2 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 641 ms
{"result": "search_processed_events:agent query=`biogen zorevunersen 4-year data | european epilepsy congress zorevunersen | stoke therapeutics zorevunersen dravet syndrome`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 62.1/72 小时、2144 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 降级 stock_tools HTTP · 1,463 ms
取价失败: Futu returned no quote - stock_quote 降级 stock_tools HTTP · 1,857 ms
取价失败: Futu returned no quote - kb_search 成功 stock_tools HTTP · 3,657 ms
{ - search_case_library 成功 stock_tools HTTP · 378 ms
{"result": "search_case_library「STOK.US」无历史决策命中(我们过去没在这些标的上决策过,或历史尚未回填)。\n◆ STOK.US：相关历史决策 12 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过"}
原文全文
展开原文 · 2,087 字
Fed hike bets, oil rally and Japan yields - what’s moving markets
BEDFORD, Mass. and CAMBRIDGE, Mass. - Stoke Therapeutics Inc. (NASDAQ:STOK) and Biogen Inc. (NASDAQ:BIIB) announced presentations of data from ongoing studies of zorevunersen for Dravet syndrome at the 16th European Epilepsy Congress, taking place September 5-9 in Athens, Greece, according to a press release statement.
The companies presented 4-year results from Phase 1/2a open-label extension studies showing sustained improvements in cognition and behavior, seizure reductions, and a generally well-tolerated safety profile. Sub-analyses examined effects on severe seizure types and quality of life.
Following treatment in the Phase 1/2a studies, 93% of patients (75 of 81) continued treatment in one of two open-label extension studies. As of the 4-year data cutoff, 77% of patients (58 of 75) remained in these studies. More than 930 doses have been administered as of July 31, 2026.
Elevated cerebrospinal fluid protein lab values occurred in approximately 94% of patients, with 59% classified as a treatment-emergent adverse event. The companies stated no serious or severe clinical manifestations have been associated with these elevations, and no cases of hydrocephalus have been reported.
The global Phase 3 EMPEROR study is underway, with results anticipated in the third quarter of 2027.
Zorevunersen is an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein production from the unaffected copy of the SCN1A gene. Most cases of Dravet syndrome are caused by mutations in one copy of this gene.
The drug has received orphan drug designation from the FDA and EMA, as well as Breakthrough Therapy Designation from the FDA and China’s Center for Drug Evaluation.
Under their collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico, while Biogen receives exclusive commercialization rights for the rest of the world.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BEDFORD, Mass. and CAMBRIDGE, Mass. - Stoke Therapeutics Inc. (NASDAQ:STOK) and Biogen Inc. (NASDAQ:BIIB) announced presentations of data from ongoing studies of zorevunersen for Dravet syndrome at the 16th European Epilepsy Congress, taking place September 5-9 in Athens, Greece, according to a press release statement.
The companies presented 4-year results from Phase 1/2a open-label extension studies showing sustained improvements in cognition and behavior, seizure reductions, and a generally well-tolerated safety profile. Sub-analyses examined effects on severe seizure types and quality of life.
Following treatment in the Phase 1/2a studies, 93% of patients (75 of 81) continued treatment in one of two open-label extension studies. As of the 4-year data cutoff, 77% of patients (58 of 75) remained in these studies. More than 930 doses have been administered as of July 31, 2026.
Elevated cerebrospinal fluid protein lab values occurred in approximately 94% of patients, with 59% classified as a treatment-emergent adverse event. The companies stated no serious or severe clinical manifestations have been associated with these elevations, and no cases of hydrocephalus have been reported.
The global Phase 3 EMPEROR study is underway, with results anticipated in the third quarter of 2027.
Zorevunersen is an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein production from the unaffected copy of the SCN1A gene. Most cases of Dravet syndrome are caused by mutations in one copy of this gene.
The drug has received orphan drug designation from the FDA and EMA, as well as Breakthrough Therapy Designation from the FDA and China’s Center for Drug Evaluation.
Under their collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico, while Biogen receives exclusive commercialization rights for the rest of the world.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。